Sanofi in $50m oncology collaboration
19-07-2018
Artur / iStockphoto.com
Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Argenx, ARGX-115, antibody, immuno-oncology, cancer treatment, cancer cells, biotechnology, immune system, collaboration, licensing agreement
